U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07435584) titled 'Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)' on Feb. 22.
Brief Summary: This is a prospective, open-label, multicenter, single-arm Phase Ib/II study evaluating the safety and preliminary efficacy of everolimus in patients with CDK12-deficient refractory metastatic colorectal cancer.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer
Intervention:
DRUG: Everolimus (Afinitor) tablets
Everolimus administered orally once daily in continuous treatment. Phase Ib dose levels include 5 mg/day, 7.5 mg/day, and 10 mg/day using a standard 3+3 dose-escalation design. Phase II p...